Next Article in Journal / Special Issue
The Genetic Diversity and Evolution of HIV-1 Subtype B Epidemic in Puerto Rico
Previous Article in Journal / Special Issue
Local Health Departments’ Activities to Address Health Disparities and Inequities: Are We Moving in the Right Direction?
Article Menu

Export Article

Open AccessArticle
Int. J. Environ. Res. Public Health 2016, 13(1), 36; doi:10.3390/ijerph13010036

Protein Kinase CK2 Expression Predicts Relapse Survival in ERα Dependent Breast Cancer, and Modulates ERα Expression in Vitro

1
College of Pharmacy, Xavier University of Louisiana, 1 Drexel Dr, New Orleans, LA 70125, USA
2
Division of Basic Sciences, College of Pharmacy and Pharmaceutical Sciences, Florida Agricultural & Mechanical University, 1415 S. Martin L. King Jr. Blvd., Tallahassee, FL 32307
*
Author to whom correspondence should be addressed.
Academic Editors: Mark Edberg, Barbara E. Hayes, Valerie Montgomery Rice and Paul B. Tchounwou
Received: 15 August 2015 / Revised: 9 October 2015 / Accepted: 10 October 2015 / Published: 22 December 2015
View Full-Text   |   Download PDF [1512 KB, uploaded 23 December 2015]   |  

Abstract

The heterotetrameric protein kinase CK2 has been associated with oncogenic transformation, and our previous studies have shown that it may affect estrogenic signaling. Here, we investigate the role of the protein kinase CK2 in regulating ERα (estrogen receptor α) signaling in breast cancer. We determined the correlation of CK2α expression with relapse free breast cancer patient survival utilizing Kaplan Meier Plotter (kmplot.com/analysis/) to mine breast cancer microarrays repositories. Patients were stratified according to ERα status, histological grade, and hormonal therapy. Luciferase reporter assays and flow cytometry were implemented to determine the impact of CK2 inhibition on ERE-mediated gene expression and expression of ERα protein. CK2α expression is associated with shorter relapse free survival among ERα (+) patients with grade 1 or 2 tumors, as well as among those patients receiving hormonal therapy. Biochemical inhibition of CK2 activity results in increased ER-transactivation as well as increased expression among ERα (+) and ERα (−) breast cancer cell lines. These findings suggest that CK2 may contribute to estrogen-independent cell proliferation and breast tumor progression, and may potentially serve as a biomarker and pharmacological target in breast cancer. View Full-Text
Keywords: CK2; estrogen receptor (ERα); relapse free survival; breast cancer CK2; estrogen receptor (ERα); relapse free survival; breast cancer
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Williams, M.D.; Nguyen, T.; Carriere, P.P.; Tilghman, S.L.; Williams, C. Protein Kinase CK2 Expression Predicts Relapse Survival in ERα Dependent Breast Cancer, and Modulates ERα Expression in Vitro. Int. J. Environ. Res. Public Health 2016, 13, 36.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Environ. Res. Public Health EISSN 1660-4601 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top